Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-04-30

Development of efficient cellular systems for industrial production of human recombinant collagens to be used as biomaterials and in oral tolerance

Objetivo



Of the 19 known types of collagen, commercial use is presently limited to type I collagen used as biomaterial and type II collagen used as a therapeutic, because only these collagen types are readily available from animal tissues, and no human sources exist. Collagens can be used as components of medical devises, in injectable form, and in drug delivery. A new field of application is oral administration of collagens in certain autoimmune diseases, such as rheumatoid arthritis.
Despite the obvious need for recombinant human collagen, production of recombinant collagen with cost-effective expression systems, such as insect cells, yeast or bacteria, have been hampered by the complex post-translational modifications required for production of collagens.
The objective of the proposal is the development of cell lines of industrial importance, namely insect cells and yeast, to allow expression of native-like triple-helical recombinant human collagens.
As a result of co-expression of human collagens and human prolyl 4hydroxylase, the key enzyme of collagen synthesis, we have successfully produced large quantities of native-like triple-helical human type II and III collagens in insect cells. Furthermore, our results suggest that by using the multi-gene expression approach it will be possible to modify yeast to produce even higher amounts of human collagen. The application combines an integrated approach by academic and SME partners to further develop means of producing cost-efficiently in large-scale any human and animal collagens using recombinant technology, and to evaluate the properties of the produced recombinant collagens in order to allow selection of the most suitable production system for the various collagens and to understand the biological diversity of the them. A single group could not set up the proposed range of expression systems, nor could a single group assess all the qualities of the produced proteins. Therefore, comparison of these several expression systems is only possible as a joint, task-oriented venture between the different partners of this proposal.
Several problems can be circumvented by the recombinant technology; it will be possible to produce in unlimited quantities any type of collagen with important functions, but occurring in trace amounts or in insoluble form in tissues, thus enabling full exploitation of the biological diversity of the members of the collagen family; avoidance of genetic differences posed by administration of nonhuman collagens found to cause allergic reactions in some patients, and improvement of efficacy in applications requiring immune response, and; the avoidance of health risks in the form of viruses and prions. Thus the application will lead to the development of safe, reproducible and sustainable bioprocesses, which will increase the health of the population, and to the creation of new job opportunities in Europe.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..

Para utilizar esta función, debe iniciar sesión o registrarse

Programa(s)

Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.

Tema(s)

Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.

Convocatoria de propuestas

Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.

Datos no disponibles

Régimen de financiación

Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.

CSC - Cost-sharing contracts

Coordinador

University of Oulu
Aportación de la UE
Sin datos
Dirección
52 A,Kajaanintie 52 A
90220 Oulu
Finlandia

Ver en el mapa

Coste total

Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.

Sin datos

Participantes (4)

Mi folleto 0 0